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II. Introduction 
 
 Chlamydia trachomatis is an obligate intracellular bacterial pathogen that is the 
causative agent of sexually transmitted infections (STI) and the ocular disease known 
as trachoma (CDC.gov). Trachoma is the leading cause of preventable blindness 
worldwide and most heavily affects developing nations (WHO.org). C. trachomatis 
causes over 1.5 million STIs each year in the U.S. alone and is of particular concern to 
women as 70–80% of genital tract infections are asymptomatic and 15–40% ascend to 
the upper genital tract, which can lead to serious diseases including pelvic inflammatory 
disease, infertility, and ectopic pregnancy2. C. trachomatis STIs have also been shown 
to facilitate the transmission of HIV and are associated with increased risk of cervical 
cancer in HPV-infected women2. Although chlamydial infections are currently treatable 
with antibiotics, drug resistance has been observed in vitro, treatment failure occurs 
clinically (although the underlying cause of failure remains unclear), and chlamydial 
reservoirs in the intestine are not susceptible to drug concentrations that are effective in 
clearing genital tract infections. In addition, a vaccine has not been developed3. 
Collectively, the large numbers of infections and sub-optimal methods available for 
treatment and prevention suggest that alternative approaches are needed for 
combatting C. trachomatis. 
 
  
 
 
  
Figure 1. The biphasic developmental cycle of Chlamydia. Chlamydia 
differentiates between the infectious elementary body (EB) and the replicative reticulate 
body (RB). Chlamydia begins the infection in the EB form before differentiating into the 
RB to replicate within an inclusion; after multiple replications, the RBs will 
asynchronously differentiate back into EBs before exiting the cell. Under stress 
conditions, Chlamydia will enter a form of low activity termed persistence. Times are 
given in terms of hours post infection (hpi).  
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 C. trachomatis has been shown to undergo a unique biphasic developmental 
cycle in which it differentiates between two functionally distinct forms5 (Fig 1). At the 
initial time of infection, C. trachomatis exists in its infectious form known as the 
elementary body, or EB. The EB is an electron dense structure that initiates cellular-
uptake and creates a vacuole out of the host cell’s membrane termed an inclusion. 
Proteins required for central metabolism and glucose catabolism were more prevalent in 
the EB form, suggesting that a basal metabolism is required outside of the cell to 
facilitate EB maintenance and cellular invasion4. Within the inclusion, C. trachomatis will 
then differentiate into the reticulate body (RB) form which is characterized as a larger 
and less dense structure that replicates within the inclusion. In the RB form, C. 
trachomatis synthesized more proteins associated with protein synthesis, ATP 
transport, and nutrient transport suggesting that the RB form is more focused on 
utilizing available nutrients, increasing cellular mass, and obtaining resources to divide 
and eventually differentiate back into the EB form4.  
 
 The different forms and “life-styles” of the EB and RB necessitate differences in 
gene activation and protein content. Multiple transcriptomic and proteomic studies have 
documented these differences. Consequently, Chlamydia need a mechanism to aid in 
proteome turn-over during differentiation. Additionally, and conserved amongst other 
organisms, Chlamydia also require a system for degrading proteins that are mis-folded, 
damaged, or no-longer needed. While mechanisms carrying out both limited and global 
protein degradation would appear to be essential for chlamydial growth and 
development, making them excellent therapeutic targets, it remains unknown how 
protein degradation occurs in these highly significant pathogens. 
 
 
 
 
 
Figure 2 The Clp system. The Clp proteins will form homo-oligomers of heptamers 
(ClpP1/P2) and hexamers (ClpC/X) which will then oligomerize together (A). While the 
proteases can function without ATP, the adaptors are ATP-dependent. These protease 
heptamers are normally seen with a narrow opening, but the activating compounds can 
aid in opening up the barrel (B).   
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 The Clp protease system is a conserved protein complex that is responsible for 
regulating proteomic turnover in bacteria and some eukaryotes (Fig 2). This system is 
comprised of two main parts: the proteasome complex comprised of ClpP (the “trash-
compactor”) and various adaptor proteins (the “trash-collectors”) that target proteins to 
and help to feed proteins into the proteasome. All chlamydial genomes appear to have 
components of the Clp system based on annotation and we hypothesize that the Clp 
system is essential for chlamydial development and therefore infection.  The protease 
complex is comprised of the ClpP protein(s) (ClpP1 and ClpP2 in Chlamydia) while the 
adaptors for Chlamydia are ClpC and ClpX. These proteins are non-functional in their 
single form, meaning one ClpP protein has no protease activity. However, when it 
oligomerizes with other ClpPs they form a barrel unit comprised of seven proteins. This 
heptameric barrel will then oligomerize on top of a second barrel to create the active 
dodecatetramer form. In this double-barrel form, the ClpP proteasome can only degrade 
small peptides and a limited number of unfolded protein substrates as the opening at 
the top of the double barrel is relatively narrow. As a method of regulation, the adaptor 
protein will open the barrel and selectively target proteins to the proteosome. ClpC and 
ClpX will each form a hexameric barrel, which will then bind to the top and bottom of the 
ClpP double barrel and unfold proteins to feed them into the barrel. In Bacillus subtilis, it 
has been shown that arginine phosphorylation via McsA/McsB will target specific 
proteins for degradation, similar to ubiquitination in eukaryotes, which the adaptor 
proteins will respond to and only open the proteasome for those targeted proteins10.  
 
As the Chlamydia genome is small (1.039 megabases) due to reductive evolution 
during its life-span as an obligate, intracellular bacterium, it is expected that it only 
encodes for those proteins absolutely necessary for survival6. For this reason, it is 
interesting to note that Chlamydia encode two paralogs of the ClpP protein, ClpP1 and 
ClpP2. This protein is a well characterized protease in other organisms; however, in 
most other organisms, such as Escherichia coli, there is only one ClpP. In the 
organisms that encode two ClpPs they have been shown to interact with each other, 
such as in Mycobacteria7. As the Clp proteins have been shown to interact with each 
other in other organisms it is possible they might in Chlamydia as well; however, it is 
also possible they preform distinct functions as shown in Pseudomonas9.   
 
 The increased prevalence of antimicrobial resistant strains across clinically-
relevant bacterial species has led to a frantic search for new antimicrobials and 
antimicrobial targets. The essentiality of the Clp system based on genetic studies in a 
number of bacteria makes it an attractive target for drug development. ClpP activating 
compounds have been identified that will open up the ClpP proteasome to cause 
unregulated degradation of proteins in other organisms7.  These activating compounds 
are the acyldepsipeptides (ADEP) and activators of cylindrical proteases (ACP) and 
they have distinct mechanisms of action. In Bacillus subtilis the ADEP compounds were 
crystalized in their bound form to the ClpP proteins and it was discovered they bind to 
the H pocket of the formed oligomers, hypothetically mimicking the binding of the 
adaptor proteins, and open the double barrel11. ACPs, in comparison, have been seen 
to bind at two different regions, the H pocket and the C pocket, and are hypothesized to 
4 
 
steady the formation of the double barrel that is expected for the ClpP proteins11. Both 
approaches lead to the same desired result – lethality for the bacterium. 
 
 For this study, we hypothesized that the Clp system plays an essential role in the 
proteomic turnover needed for differentiation between the EB and RB, and therefore is 
required for the developmental cycle. As a first test of our hypothesis we sought to 
determine if the ClpPs were functional using various in vitro approaches and whether 
ClpP functionality is required for chlamydial growth. The latter point was tested using a 
cell-culture infection model with various ACPs. We determined that 1) ClpP2, but not 
ClpP1, appears to be active in vitro under the conditions tested, 2) that ClpP2 is 
expressed during development, and 3) that ClpP2 activating compounds severely inhibit 
chlamydial growth in tissue culture. 
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III. Results 
 
 
We initially sought to determine if the clp genes were expressed in C. trachomatis. This 
work was done by Scot Ouette's group (data not shown) and corroborated by our lab by 
looking at protein production through Western blot analysis. To detect protein 
expression, we took advantage of a prior study on Pseudomonas aeruginosa, in which 
antibodies were synthesized against PA1801 (P. aeruginosa ClpP1) and PA3326 (P. 
aeruginosa ClpP2). The antibody against P. aeruginosa ClpP1 showed amino acid 
sequence similarity to C. trachomatis ClpP2 and it was confirmed through western blot 
analysis that the antibody would bind ClpP2 (Fig 3A). Using this data, it was found that 
ClpP2 is expressed in C. trachomatis at 24, 30, and 40 hours post infection (Fig 3B) 
when RBs would be converting to EBs. 
 .  
 
 
 
 
 
 
Escherichia coli BL21(de3) was used to produce the respective ClpP proteins using the 
lac operator and T7-promoter regulated pLATE31 vector (Fig 4). Each Clp protein gene 
was cloned into the multiple cloning site of the pLATE31 vector using ligation 
independent cloning.   
Figure 3 Western blot analysis of ClpP2 expression in C. trachomatis. Purified 
proteins were run on 12% SDS-PAGE gels and then transferred to nitrocellulose for anti-
ClpP2 tag western blot (A and B). Coomassie brilliant blue (C) and anti-MOMP western blot 
(D) controls were also run. Expected molecular weights for the recombinant proteins: ClpP1 
22 kDa and ClpP2 23 kDa,  
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The proteins were then affinity purified using cobalt-based immobilized metal 
affinity chromatography. The ClpP1 product appeared to have two proteins at different 
sizes (Fig 5) as seen by the double band. It was determined through mass spectrometry 
that the smaller band protein sequence began at a second methionine located within the 
ctl0690 gene, while the larger band had the predicted native start site methionine (Fig 
5). To address this potential problem as the N-terminal sequence is crucial for 
oligomerization, a mutant of the ClpP1 protein was created where the second and third 
internal methionines were replaced with an isoleucine and leucine, respectively. This 
mutant was called ClpP1SDM. ClpP2 did not express this double band and was 
therefore utilized in its native form.  As a positive control, E. coli ClpP was expressed 
and purified for assays (ClpPec). Purifications of ClpP1(SDM) and ClpP2 were 
completed multiple times.  
 
Figure 4 Clp protein producing plasmids. The clpP1 (ctl0690), clpP2 (ctl0075), 
clpP1SDM, and clpPec genes were cloned into pLATE31 at the multiple cloning site (starred 
region) to produce C-terminal His-tagged recombinant proteins under control of the lac 
operator and T7 RNA polymerase promoter 
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Activity was assessed for ClpP1, ClpP2, ClpP1SDM, and ClpPec using an 
oligomerization assay, digestion of a small fluorescent peptide, and digestion of casein 
in the presence or absence of potential activating compounds. Oligomerization assays 
were performed using native-PAGE gels and demonstrated that ClpPec formed the 
strongest dodecatetramer, while ClpP2 and ClpP1 formed primarily the heptamer with 
modest dodecatetramer, while ClpP1SDM appears to only form the heptamer (Fig 6). 
These results suggest an in vitro functionality ranking of ClpPec being more active than 
ClpP1 and ClpP2, which are about equal, and those are more active then ClpP1SDM. 
To more directly address protease activity further experimentation was performed.  
 
 
                      
 
 
 
 
Figure 5 Purification of recombinant ClpP1, ClpP1SDM, ClpP2, and ClpPec. 
Purified proteins were run on 12% SDS-PAGE gels and then either stained with Coomassie 
Brilliant Blue (A) or transferred to nitrocellulose for anti-His tag western blot (B). Expected 
molecular weights for the recombinant proteins: ClpP1 22 kDa, ClpP1SDM 22 kDa, ClpP2 23 
kDa, ClpPec 24 kDa. 
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Activity was initially assayed using a fluorescent substrate, Suc-Leu-Tyr-ACM, 
which when cleaved releases AMC to fluoresce (Fig 7A). The fluorescence readout is 
directly proportional to the level of ClpP activity and readings were taken over six hours.  
It was seen that while ClpPec was very active throughout the assay, ClpP1 and 
ClpP1SDM were both found to be inactive, and ClpP2 had detectable, but modest 
activity (Fig 7B). There was a two-fold increase in fluorescence between ClpP1 (at 
baseline) and ClpP2 (Fig 7C).  
 
 
Figure 6 The ClpP proteins form oligomers. Purified proteins were run on a Native-
PAGE gels and then stained with Coomassie Brilliant Blue. Expected molecular weights for 
the heptamer and dodecatetramer oligomers: ClpP1 154/308 kDa, ClpP1SDM 154/308 kDa, 
ClpP2 161/322 kDa, ClpPec 168/336 kDa. 
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 An in vitro assay supported these findings, in which β-Casein was used to test 
the protease activity of the ClpP analogs with and without the activating compounds. β-
Casein is a much larger protein than Suc-Leu-Tyr-AMC, and the ClpP analogs should 
be unable to degrade it without an adaptor protein to unfold the substrate or an 
activating compound to increase the barrel opening. It was found that ClpPec, ClpP1, 
and ClpP2 were all unable to degrade β-casein. However, upon the addition of 10 µM of 
ADEP1, and 500 µM of the ACP1, ACP1a, and ACP1b β-casein was mostly degraded 
by ClpPec and ClpP2 after 3 hours (Fig 8). 
 
 
 
 
 
 
 
Figure 7 ClpP2 is active in vitro while ClpP1 is not. The ClpPs (1 µM) were 
incubated with the fluorometric peptide Suc-Luc-Tyr-AMC at 37°C for 6 hours. The peptide 
fluoresces when cleaved at the site indicated (A). Relative fluorescence units were recorded 
at five-minute intervals and the average of all time course traces are shown in (B). The 
average values are reported with standard error in (C, n = 3).   
Figure 8 ACP and ADEP activate ClpP2, but not ClpP1. Reactions were run at 
37°C for 3 hours with 1 µg of casein. ADEP1 was used at 10 µM and other compounds 
were used at 500 µM. Representative gels are shown. 
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After demonstrating that: 1) ClpP2 is expressed and the protein could be 
detected during growth, 2) ClpP2 oligomerizes, 3) ClpP2 can cleave a peptide 
substrate, and that 4) ClpP2 activity is stimulated towards casein using ACP and ADEP, 
we sought to test whether ClpP2 activation would disrupt chlamydial growth. 
Compounds were previously identified as antibacterial like compounds in other 
organisms specifically targeting the bacterial Clp system. These activating compounds, 
known as acydepsipeptides (ADEP compounds) and activators of cylindrical proteases 
(ACP compounds), have been seen in E. coli to enhance ClpP activity. ADEP1, ACP1, 
ACP1a, and ACP1b were seen in vivo to enhance C. trachomatis Clp system activity 
(ADEP1 not pictured) (Fig 9). C. trachomatis strain DFCT28 has been modified to 
express GFP. Infected cells were treated with 50 µg/mL of each specified activating 
compound in duplicate and the chlamydial growth was inhibited in all wells. The 
untreated infected cells and DMSO treated infected cells showed no change in growth 
(Fig 9).  
 
 
 
 
 
 
 
Figure 9 ClpP activating compounds inhibit C. trachomatis growth. In vitro results 
were corroborated with an in vivo assay. HeLa cells were infected with C. trachomatis at a 
MOI of 0.2 and activators were used at a concentration of 50 µg/mL. Wells were imaged at 
24 and 48 hours post infection (24 shown). No bacteria were present in the presence of 
inhibitors at 48 hours post infection as well. 
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IV. Discussion 
 
In this study, we sought to biochemically characterize the C. trachomatis proteins 
ClpP1 and ClpP2 with the goal of validating the Clp system of Chlamydia as a 
therapeutic target. Our data is indicative of the Clp system playing an essential role in 
the development of Chlamydia, as it is expressed at specific time points in the 
development cycle and unregulated activity caused chlamydial cell death.  
 
This study began by testing Clp protein expression in C. trachomatis to 
determine at what point in the developmental cycle the Clp proteins may regulate 
proteomic turnover. To do so, an antibody was identified as specific for Pseudomonas 
aeruginosa ClpP1 and C. trachomatis ClpP2. When a western blot was run using 
infected L2 cells at varying points in the developmental cycle, ClpP2 was detected at 
24, 30, and 40 hours post infection. This correlates to the differentiation from RB back to 
EB at about 24 hours post infection up until the release of EBs from the host at about 40 
hours post infection. This correlates well with our hypothesis that the Clp system 
regulates proteomic turnover from one developmental form to the next as it is initially 
expressed at the specific time point in the developmental cycle known for that exact 
transition. However, ClpP2 expression is lacking at the initial transition from elementary 
to reticulate body, though this is not entirely surprising as we are open to the idea that 
the elementary body form comes prepackaged with all the proteins and nutrients 
needed to make this single transition. It is also possible that ClpP1 is critical for early 
steps, but it may require an adaptor protein for functionality (such as ClpX/C) that has 
yet to be identified.  
 
As discussed earlier, ClpP proteins are not active until they are in their 
dodecatetramer double barrel. From the oligomerization assays it became clear that the 
purified ClpP proteins from C. trachomatis did not readily oligomerize, while those from 
E. coli did. The E. coli band was significantly stronger and this could be the result of 
expressing the protein, ClpPec, in its original organism, which would easily lend to 
proper folding as it is in its ideal environment. Chlamydial proteins, on the other hand, 
were not in their ideal environment for expression, as they were expressed in E. coli, 
rather than C. trachomatis. Soluble protein was purified and some oligomerized forms of 
the protein could be seen, but they were stronger at the expected size for heptamers 
rather than the dodecatetramers. This does not mean that the proteins are inactive, 
however, as the fluorescence and Casein assays are indicative of ClpP2 activity, simply 
that with the current expression system the proteins may be less active than they would 
be in their native form. For this reason, it is important to note our in vivo studies that 
show a low amount of activating compound is still enough to cause Chlamydia cell 
death. In their native environment, ClpP activity may be stronger than our in vitro 
studies have shown with the current models.  
 
While we initially saw ClpP2 can readily degrade a small fluorescent peptide, 
ClpP1 was unable to do so. We hypothesized this may be due to the two ClpP1 proteins 
that were identified on an SDS-PAGE gel and verified by mass spectrometry.  This led 
us to create a mutant of ClpP1 through site directed mutagenesis to replace the internal 
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methionines with an isoleucine and leucine, creating ClpP1SDM. When this mutant was 
tested in the same fluorescence assay, it did not show the same level of activity as 
ClpP2. One purification did show a high level of activity, but later multiple purifications 
did not, causing us to conclude the initial purification may have been contaminated with 
ClpPec. From this it appears that ClpP1 may need an additional protein/peptide for 
proper function, or the isoleucine and leucine rendered it inactive and a different mutant 
needs to be created.  
 
This finding was further supported by the β-Casein assay that found ClpP2, with 
the assistance of activating compounds, could degrade β-Casein while ClpP1 could not. 
This lack of activity is indicative of there either not being a fully formed ClpP1 double 
barrel, which is supported by the oligomerization assay, a mix of proper ClpP1 proteins 
and those lacking 4 amino acids, which might lead to inactivity, or ClpP1 is simply 
inactive in Chlamydia. It is unlikely that ClpP1 has no activity considering the chlamydial 
genome is so small, as previously discussed, but still possible.  
 
The in vivo assay is incredibly important to this study as it exemplifies the 
importance of the Clp system in Chlamydia's developmental cycle, based on the 
clearance of the infection upon the addition of the activating compounds. Also, as seen 
in the non-GFP images, the cells that had the infection cleared look healthy and normal, 
supporting the idea that while the activating compounds are non-specific among 
bacterial species, they might not target the hosts' Clp system or inhibit cells under the 
conditions tested.  
 
From this study, we were unable to determine any interaction between the ClpP1 
and ClpP2 proteins nor determine if there is any specificity between each ClpP analog 
and the ClpC/X adaptor proteins. This is a source for further experimentation and study 
as well as the determination of more specific activating compounds. While the in vivo 
assay supported that the hosts Clp system was unaffected by the activating compounds 
there are still beneficial microbiota in multicellular organisms that an ideal treatment 
would not target.  Other activating compounds have already been identified, but they did 
not exhibit species specificity and had a lessened effect on the Chlamydia in vivo. 
 
Based upon findings from this study, the Clp system appears functional in 
Chlamydia and our in vitro and in vivo results support the Clp system as a novel target 
for drug development.  
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V. Methods 
 
Cloning of the ClpP genes 
 
Table 1: Primers used to isolate genes. The primers were designed using Clone 
Manager.  
 
Primers Used 
Gene Forward Primer Reverse Primer 
ctl0075 AGAAGGAGATATAACTATGACGTT
GGTACCATACGTTGTTGAAG 
GTGGTGGTGATGGTGATGGCCAG
ACGCAATACTCTTATCTTTTGTC 
ctl0690 AGAAGGAGATATAACTATGCCTGA
AGGGGAAATGATGCATAAG 
GTGGTGGTGATGGTGATGGCCCAA
GTCGTTAAAAGAGAAGAGAATCCC 
ctl0690 
mutant 
ATAGAAAGTTGTTGGATTCTCGTC
G 
CTATGACATCTTGCAACTTATGAAT
CAGTTCCCCTTCAGGCATAGTTATA
TC 
eck0431 AGAAGGAGATATAACTATGTCATAC
AGCGGCGAACGAG 
GTGGTGGTGATGGTGATGGCCATT
ACGATGGGTCAGAATCGAATCG 
 
The clpP1 (ctl0690), clpP2 (ctl0075), clpP1SDM and clpPec genes were 
amplified through PCR using the primers designated in the above table and inserted 
into the vector pLATE31using the LIC procedure as described by the Fisher Scientific 
(Kit #K1261). The primers were designed using Clone Manager and the completed 
vectors were then transformed into Escherichia coli NEB10 competent cells through 
chemical transformation and transformants were selected on LB agar plates 
supplemented with 100 µg/ml ampicillin. Clones were assessed for the gene inserts 
using PCR and the plasmid was then extracted using the GeneJet Plasmid purification 
kit (Fisher Scientific #K0502). The plasmid was then sequence verified and transformed 
into Escherichia coli BL21 (de3) through electroporation for protein expression.  
 
Protein Expression and Purification 
 
The ClpP constructs were induced at 0.5mM IPTG at 18°C for 20 hours in E. coli 
BL21 (de3). Both proteins are fused to a His tag and were purified using immobilized 
metal affinity chromatography with HisPur Cobalt Agarose resin (Fisher Scientific). The 
culture was grown in 500mL of lysogeny broth with ampicillin to an OD600nm reading of 
0.6. After induction the sample was centrifuged at 13,000g for 20 minutes, washed in 
PBS, and frozen overnight. The pellet, after thawing, was then resuspended in a 1:10-
1:12.5 solution of Buffer A. The cells were lysed through sonication in five, ten second 
bursts. The sample was again centrifuged at 13,000g for 20 minutes. The soluble 
portion was then filter sterilized into a bed of 200µL of resin. The protein was bound to 
the resin for 1 hour, after which, the resin was spun down at 700g for 5 minutes at 4°C 
and the supernatant was then discarded. The resin was washed with 400µL of Buffer A, 
centrifuged at 700g for 1 minute, and the A280 value was read until it leveled out. Then 
200µL of Buffer B was added to the resin, mixed, and centrifuged at 700g for 5 minutes. 
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This was repeated three more times. Each step was run on an SDS-PAGE gel to 
confirm protein purification and elution, and then the protein yield was concentrated by 
pooling all of the elution samples in an Amicon unit, adding 10mL of Buffer C, and 
centrifuging it at 4,000g for 90 minutes. This was repeated two more times. The final 
protein preparation was stored at -80°C and protein concentrations were determined by 
a Bradford Assay.  
 
Buffer compositions: 
Buffer A: 25mM Tris (pH 7.5), 150mM NaCl, 10mM Imidazole, 10% glycerol 
Buffer B: 25mM Tris (pH 7.5), 150mM NaCl, 300mM Imidazole, 10% glycerol  
Buffer C: 25mM Tris (pH 7.5), 150mM NaCl, 10% glycerol 
 
 
Western blots: Pseudomonas aeruginosa ClpP1 and ClpP2 antibody comparison 
and His-tag detection 
 
 The P. aeruginosa antibodies were rabbit poly-clonal antibodies and were used 
at the following concentrations: α-ClpP1 antibodies were used at a concentration of 
1:10,000, while α-ClpP2 antibodies were used at a concentration of 1:5,000. A test was 
run of α-ClpP2 antibodies with 1:2,500 with no change in results. α-His antibodies were 
mouse monoclonal and were used at a 1:2,500 concentration.  
The western blot to test for antibody compatibility was run at 300mA for an hour 
for the transfer of 200ng of each specified protein to nitrocellulose. The blot was blocked 
using milk protein (casein) for 1 hour at room temperature, the primary antibody was 
applied overnight at 4°C, and the secondary antibody was applied for 1 hour at room 
temperature.  
 The only differences that were applied to the time point western blot were that 
the transfer was run at 325mA and only 50ng of ClpP2 protein were used. For each time 
point, 25µl of C. trachomatis protein sample were used, 12µl of L2 lysate and 5µl of 
HeLa lysate were used.  
 
Oligomerization Reactions 
 
Table 2: Expected Protein Sizes of Oligomers. Protein sizes were calculated using 
the bioinformatics.org website and then multiplied by 7 or 14.  
 
Protein Sizes 
Protein Weight (with tag) Oligomer Weight 
ClpP1 22kDa Heptamer 154kDa 
  Tetradecamer 308kDa 
ClpP1SDM 22kDa Heptamer 154kDa 
  Tetradecamer 308kDa 
ClpP2 23kDa Heptamer 161kDa 
  Tetradecamer 322kDa 
ClpPec 24kDa Heptamer 168kDa 
  Tetradecamer 336kDa 
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 The oligomerization reacts were set up to run at room temperature for 40 minutes 
in Buffer D supplemented with either nothing, 1mM of ATP, or 1mM AMP-PNP. Each 
reaction had 2µg of protein. The reactions were then mixed with native-PAGE buffer 
and run on a 4-20% native-PAGE gel at 200 volts for 90 minutes. The final gel was 
stained with Coomassie brilliant blue.  
 The second and third biological replicates, run with another batch of purified 
protein were incubated only in Buffer D but for 1 hour at 37°C with 5µg of protein. This 
replicate also tested the efficacy of the ClpP activators: ACP1 and ACP1a.  
 
Buffer compositions: 
Buffer D: 25mM Tris-HCl (pH 7.5), 5mM KCl, 5mM MgCl2, 10% glycerol, 1mM DTT  
 
 
Fluorescent Peptidase Assay 
 
 These experiments were conducted by incubating 1µM of ClpP protein with 
500µM of peptide Suc-Luc-Tyr-AMC in Buffer E. Papain was used as a positive control 
at 0.1µM. Each experiment was a 50µL reaction that was run in duplicate on a 96 well 
plate and measured for fluorescence with an excitation at 340/360nm and a reading at 
440/460nm. The experiment was conducted over 6 hours at 37°C with readings taken 
every 5 minutes.  
 
Buffer compositions: 
Buffer E: 50mM Tris-HCl (pH8), 200mM KCl, 1mM DTT  
 
 
Casein Degradation Assay 
 
 
 Reactions were set up with 1µM of ClpP, 1µg of casein per time point, Buffer E 
and a specified amount of activator in an Eppendorf tube. The reaction was carried out 
at 37°C for 3 hours. The reaction was then immediately mixed with 2x Laemmli buffer 
and boiled at 90-100°C for 10 minutes. Each time point was then run on a 12% SDS-
PAGE gel for visualization. Activators were prepared by Dr. Conda-Sheridan at the 
University of Nebraska Medical Center 
 
Buffer compositions: 
Buffer E was modified to include casein at a concentration of 1µg/µL 
 
In vivo antimicrobial assay 
 
 Mouse L2 cells were infected with GFP expressing C. trachomatis at a multiplicity 
of infection of 0.2. Eight hours after being infected, wells were treated in duplicate with 
50µg/mL of the activating compound. The inclusions were then imaged 24 hours post 
infection using fluorescence microscopy.  
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